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Summary
Although malnutrition is a highly prevalent condition in the
inpatient setting, particularly in older patients with multi-
ple morbidities, the medical community has struggled to
find efficient, evidence-based approaches for its preven-
tion and treatment. From an evolutionary perspective, ill-
ness-related low appetite may be seen as a protective
response with the goal of accelerating recovery from dis-
ease by improving autophagy. In line with this, earlier trials
in the intensive care setting including severely ill patients
have demonstrated unwanted effects of overnutrition on
patient outcomes. Uncertainties regarding the best ap-
proach to the malnourished inpatient in conjunction with a
lack of strong trial data may, in part, explain the low level of
attention that hospital medical staff have paid to the issue
of malnutrition in the non-critical care inpatient setting. The
recent Effect of early nutritional support on Frailty, Func-
tional Outcomes and Recovery of malnourished medical
inpatients Trial (EFFORT) study, however, has shown that
individualised nutritional support reduces severe compli-
cations and improves mortality in medical inpatients, with
positive effects on functional outcomes and quality of life.
These results from a high quality effectiveness trial in con-
junction with other studies, such as the NOURISH trial,
should prompt us to improve our management of malnutri-
tion in the in-hospital setting. This procedure should start
with a systematic screening for risk of malnutrition of ad-
mitted patients, effective assessment of nutritional status
in multidisciplinary teams including dieticians, nurses and
physicians, and the early start of individualised adequate
nutritional support of at-risk patients to reach nutritional
goals. Understanding the optimal use of nutritional support
in patients with acute illness is complex because timing,
route of delivery, and the amount and type of nutrients may
all affect patient outcomes. Also, particularly for patients
on the medical ward, factors such as the logistics of cater-
ing, staffing to provide food and support to the patient (i.e.,
number of nurses and dieticians per patient), motivation/
understanding of the patient to eat in defiance of appetite,
the empathic human factor of nutritional care, the quality
of meals, the taste of supplements, and unnecessary fast-
ing for diagnostic or therapeutic procedures have a strong
influence on nutritional care of patients. Further research
and clinical trials are required to better understand, step
by step, how we can use clinical nutrition best to maximise
recovery of our patient and improve their functional status
and their quality of life. Such evidence regarding nutrition-
al therapy may allow us to implement personalised nutri-
tion-driven interventions in the future.
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Background
With James Lind conducting the first ever randomised con-
trolled trial in 1747 by comparing of six different treat-
ments for 12 sailors with scurvy, nutritional research really
had a promising start [1]. Hippocrates of Kos, one of the
most outstanding figures in the history of medicine, also
had great hopes for the effect of nutritional interventions to
cure disease (“Let food be thy medicine and medicine be
thy food”). Much of the current evidence regarding effects
of nutritional research, however, stems from observation-
al studies with cross-sectional or cohort-study designs, and
there is an important lack of randomised, interventional re-
search, which is needed to establish causal effects rather
than just statistical associations [2–4].
The aim of this article is to discuss the difficulties and re-
cent progress in achieving the goal of individualised nutri-
tion that fulfils todays’ criteria of “evidence-based” med-
icine by focusing on some recent trials that have
importantly advanced the field.
The concept of evidence-based nutritional sup-
port
Evidence-based medicine is an approach to medical prac-
tice intended to optimise decision-making by emphasising
the use of evidence from well-designed and well-conduct-
ed research – typically randomised trials and meta-analy-
ses from such trials. Evidence-based clinical nutrition
should use the exact same criteria for classifying evidence
by its epistemological strength and requiring that only the
strongest types can also yield strong recommendations [4].
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As such evidence has been lacking for a long time, current
clinical practice guidelines, including the European Soci-
ety for Clinical Nutrition and Metabolism (ESPEN) [5] and
the American Society for Parenteral and Enteral Nutrition
(ASPEN) [6], give only weak recommendations to con-
sider initiating nutritional support, defined as provision of
oral, enteral or parenteral nutrition, during the hospital stay
of medical patients identified as at risk of malnutrition.
Association of malnutrition and patient out-
comes
It is well known from previous studies that protein-energy
malnutrition is a strong and independent risk factor asso-
ciated with mortality, prolonged length of stay in the hos-
pital and higher rates of complications including infections
[7, 8]. There is strong evidence showing dramatic muscle
loss occurring within the first days of bed rest after hospi-
tal admission, particularly in patients with disease-related
loss of appetite and thus low food intake [9, 10]. Therefore,
it seems obvious that correction of malnutrition by use of
nutritional treatment could have a beneficial effect on out-
comes [11]. Yet, to the surprise of many, studies conduct-
ed in intensive care settings found no benefit in early full-
replacement feeding of critically ill patients; in contrast,
an increase in complications was observed [12, 13]. These
ICU trials led to the current concept of using hypocaloric
nutrition with sufficient amounts of protein during the first
week in the ICU. The negative effects of nutritional (over-
) treatment observed in these trials have been explained
mainly by two factors: risk of refeeding syndrome [14, 15]
and interference of nutritional intervention with autophagy
– a process that is needed for detoxification of cells during
stress and acute disease [16]. A benefit of disease-related
anorexia during an acute episode of illness may also seems
plausible, as anorexia is an integrated part of the acute
physiological response to acute illness [17]. Importantly,
in chronically ill patients, this physiological response may
have gone wrong, thereby negatively influencing recov-
ery and outcomes. Thus, in patients with multiple chron-
ic diseases, who have lost weight and muscle mass over
time, use of an adequate nutritional support has potentially
a positive role.
Recently, there has been publications of important trials
that may help us to better understand the benefits of nutri-
tional support when used in the right patient, at the right
time and in the right amount. These trials, which are dis-
cussed in more detail below, are important to strengthen
the evidence of current clinical nutritional research and to
get a step closer to evidenced-based personalised nutrition.
The role of nutrition in the prevention of dis-
ease: the PREDIMED trial
In addition to observational research reporting associations
of different nutrients and types of food with health out-
comes, several large randomised trials have demonstrated
an impact of nutritional interventions on mortality and
morbidity. Most prominently, the PREDIMED (Preven-
ción con Dieta Mediterránea) trial showed positive effects
of a Mediterranean diet supplemented with extra-virgin
olive oil or with mixed nuts, as compared with a control di-
et with advice to reduce dietary fat, on cardiovascular and
metabolic disease [18]. In fact, the risk for a major cardio-
vascular event including myocardial infarction, stroke, or
death from cardiovascular causes over the period of 5 years
was reduced by about 1% from (from 4.4 to 3.4%) in the
intervention group [18]. Importantly, the intervention was
not associated with a change in weight, and thus the qual-
ity of nutrition, presumably in regards to types of fat, may
have made this difference in outcomes. As a limitation to
the generalisability of results and the understanding of the
specific effect of single nutrition components, the inves-
tigators used a bundled approach with several recommen-
dations including consumption of wine, vegetables among
others, in the intervention group. In addition, control group
patients may have changed their diet, shifting from fat to
high sugar foods. Also, the trial was originally published
in 2013 and republished in 2018 owing to protocol devia-
tions. Despite all these challenges in the interpretation of
the results, the trial has been important for the understand-
ing that specific diets have (strong) preventive effects and
influence clinical outcomes and cardiovascular health.
Effect of nutritional support on clinical out-
comes in hospitalised patients
Up to 30% and more of patients hospitalised in medical
wards are either at increased risk for malnutrition or mal-
nourished [19]. Malnutrition has been associated with ad-
verse outcomes, independently of the underlying disease
and other confounders [7, 8], whereas interventional re-
search investigating whether provision of nutritional sup-
port has positive effects on outcomes has been scarce. Two
meta-analyses focusing on randomised trials in the med-
ical inpatient setting that compared patients receiving nu-
tritional interventions with patients receiving usual care
demonstrated that nutritional therapy increases energy and
protein intake, as well as body weight, but showed only
few significant effects on clinical outcomes [20, 21]. Im-
portantly, both meta-analyses also pointed out the low
study quality, with high heterogeneity across trials and risk
of bias. Thus, the lack of significant results regarding mor-
tality and morbidity may be due rather to methodological
issues and low statistical power, and not lack of effective-
ness per se.
The above mentioned meta-analysis [20], however, did not
include two more recent, large-scale trials investigating the
effects of nutritional interventions on outcomes of medical
inpatients.
Results of the NOURISH trial
First, the NOURISH (Nutrition effect On Unplanned Read-
missions and Survival in Hospitalised patients) trial, a mul-
ticentre, randomised placebo-controlled trial, evaluated the
effect of a high-protein oral nutritional supplement (HP-
HMB) containing beta-hydroxy-beta-methylbutyrate (a
leucine metabolite) versus a placebo supplement (with low
protein and no HMB) in malnourished hospitalised older
patients. The trial was industry-sponsored and included
652 older adults who were malnourished (as assessed by
the Subjective Global Assessment) and hospitalised for ei-
ther congestive heart failure, acute myocardial infarction,
pneumonia, or chronic obstructive pulmonary disease; it
had several exclusion criteria including a previous history
of diabetes among others. The trial failed to show a differ-
ence in 90-day non-elective readmission rate and incidence
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of death, which was the primary composite endpoint, but
showed positive effects on secondary endpoints. In fact,
there was a significant reduction in 90-day mortality in the
intervention group compared with the placebo group (4.8
vs 9.7%), resulting in a number needed to treat (NNT) of
20 [22]. However, it remains unclear whether this benefi-
cial effect is attributed to the specific formula or the differ-
ence in proteins, given that control patients received a low
protein/energy placebo product.
Results of the EFFORT trial
Second, the Effect of early nutritional support on Frailty,
Functional Outcomes and Recovery of malnourished med-
ical inpatients Trial (EFFORT), a pragmatic, investigator-
initiated, open-label, non-commercial, multicentre, ran-
domised controlled trial, tested the hypothesis that
individualised nutritional support to reach protein and en-
ergy goals reduces the risk of adverse clinical outcomes in
medical inpatients at nutritional risk [23, 24]. This effec-
tiveness trial was conducted in eight Swiss hospitals and
randomised 2028 medical inpatients at nutritional risk, de-
fined by a Nutritional Risk Screening (NRS 2002) score
≥3 points, to receive protocol-guided individualised nu-
tritional support to reach protein and energy goals (inter-
vention group) or standard hospital food (control group).
The composite primary endpoint was adverse clinical out-
come defined as all-cause mortality, intensive care admis-
sion, non-elective hospital readmission, major complica-
tions and decline in functional status at 30 days with
mortality being the principal secondary endpoint of inter-
est. In the trial, nutritional support was provided according
to a previously established nutritional protocol [25], which
is in line with the ESPEN guidelines for polymorbid med-
ical inpatients [5]. For each patient, individualised nutri-
tional energy and protein goals were defined upon hospital
admission. According to the protocol, energy requirements
were predicted using the weight-adjusted Harris-Benedict
equation or by indirect calorimetry [26]. Additionally, pro-
tein intake was set at 1.2–1.5 g/kg body weight per day,
with lower targets for patients with chronic renal failure
without renal replacement therapy (0.8 g/kg body weight
per day). The protocol also proposed nutritional interven-
tions to reach these goals by the establishment of an in-
dividual nutritional plan by a trained registered dietician.
The initial focus was on the use of oral nutrition including
adjustment of meals according to patient preferences, food
fortification (such as enrichment of hospital food by
adding protein powder), addition of between-meal snacks
and oral nutritional supplements. Escalation of nutritional
support to enteral tube feeding (or parenteral feeding) was
recommended if at least 75% of energy and protein targets
could not be reached through oral feeding (or enteral feed-
ing) within 5 days. Upon hospital discharge, patients re-
ceived dietary counselling for the continuation of nutri-
tional support and, if indicated, a prescription for oral
nutritional supplements in the outpatient setting – although
this was not enforced by the protocol.
The EFFORT trial found that nutritional goals could be
reached, mostly by use of oral nutrition including oral nu-
tritional supplements, in a majority of intervention group
patients, with 79% reaching energy goals and 76% reach-
ing protein goals. In a few patients there was an escalation
to either enteral or parenteral feeding. More importantly, in
the evaluation of the primary endpoint, the trial reported
that by 30 days, 232 of 1015 patients (22.9%) in the in-
tervention group experienced an adverse clinical outcome
compared with 272 of 1013 (26.9%) of the control group
patient, corresponding to a number needed to treat of 25 to
prevent one severe complication. There were also signifi-
cantly lower rates of death in the intervention group com-
pared with the control group (7.2 vs 9.9%) and notable im-
provements in functional outcomes and in quality of life
measures. Thus, these results provide strong evidence for
the concept of systematically screening medical inpatients
on hospital admission in terms of nutritional risk, inde-
pendent of the medical condition, followed by a nutrition-
al assessment and initiation of nutritional support in at-
risk patients. The results also contradict the hypothesis that
provision of nutritional support during the acute phase of
illness would have harmful effects – at least in the non-crit-
ically ill setting.
Still, the results of EFFORT should not be used to support
full-replacement nutritional therapy in medical inpatients.
Harmful effects of “overfeeding” have been demonstrated
in previous studies [12, 17]. The nutritional algorithm used
in the EFFORT trial was thus not very aggressive and rec-
ommended escalation of nutritional support to enteral and
parenteral nutrition if patients met only <75% of nutrition-
al goals. Thus, EFFORT rather proved that the concept
of using individualised nutritional support with an aim of
reaching at least 75% of nutritional goals has better clinical
outcomes compared with not providing nutritional therapy
on top of hospital food. The implementation of the nutri-
tional protocol was based on a pathophysiological rationale
and results of observational as well as smaller randomised
trials. Unlike the NOURISH trial, which investigated the
effect of a specific nutritional formula [22], within EF-
FORT a variety of nutritional support strategies were used
by trained dieticians to reach nutritional goals. Thus, EF-
FORT does not provide evidence regarding single nutri-
tional components or types of foods, but rather proves that
the multifaceted strategy of providing nutritional therapy
to reach protein and energy goals during the acute phase of
illness is beneficial for patients.
Outlook and conclusions
Understanding the optimal use of nutritional therapy is
highly complex because timing, route of delivery, and the
amount and type of nutrients may all have important con-
siderations and potentially affect patients' outcomes.
Whereas in the NOURISH trial one specific product was
tested, namely a high-protein oral nutritional supplement
(HP-HMB), the EFFORT trial asked the basic question of
whether nutritional therapy based on different nutritional
components during the hospital stay improves clinical out-
comes of medical patients at nutritional risk compared with
standard hospital food. Both trials provide important infor-
mation to strengthen the evidence regarding the use of nu-
tritional therapy during the acute phase of illness, but both
trials also suggest important questions to be addressed by
future clinical trials.
Despite strong associations between malnutrition and ad-
verse outcomes, there has for long been a lack in interven-
tional research proving causal inferences. The NOURISH
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and the EFFORT trials have now provided evidence that
nutrition improves patients outcomes beyond just weight
and food intake. From the results of these trials, we now
know that individualised nutritional support in medical
inpatients at nutritional risk is effective in lowering the
risk of adverse outcomes and mortality at 30 days. These
findings thus strongly support the concept of systematic
screening of medical inpatients, followed by a nutritional
assessment and initiation of individualised nutritional sup-
port in at-risk patients. It is now important to look closer at
clinical nutrition per se and ask whether certain proteins, in
regard to quality or quantity, have better or worse effects.
The selection, timing, dose and feasibility of nutritional
treatment should be evaluated as carefully as those of any
other therapeutic intervention, with the aim of maximising
efficacy and minimising side effects as well as costs.
The term “personalised medicine” relates to the observa-
tion that not all patients show the same response to med-
ical therapies. For example, some patients may derive a
marked benefit from nutritional therapy, whereas other pa-
tients may have no benefit or may even suffer harm from
that intervention. Whether or not a patient benefits from
nutritional therapy may relate to illness-specific factors
(e.g., comorbidities, acute vs chronic course) or patient-
specific factors (e.g., age, gender, comorbid illnesses). Ad-
ditionally, there may be specific genetic traits that will
help in identifying patients who may or may not bene-
fit from nutritional therapy. The metabolomic approach,
among others, allows measurement of a plenitude of differ-
ent markers and signatures, and correlation of these with
specific patient phenotypes [27–30]. This should allow
us to find specific markers and combinations of markers
(termed “signatures”) that would enable us to predict re-
sponse to nutritional treatment and thus, in the future, pro-
vide more personalised nutritional clinical treatment of pa-
tients. Also, it will be important to understand the effects of
nutritional interventions on the microbiome, which might
play a key role in answering this question.
Instead of pragmatically using nutritional interventions
based on a few rigorous randomised trials, we should go
back to where James Lind started in 1747 and perform the
large and well-conducted trials needed to truly understand
the potential of nutritional therapy to positively influence
recovery from disease in the medical inpatient population.
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